We aimed to determine the safety and effectiveness of percutaneous endobiliary radiofrequency ablation of malignant biliary obstructions with a temperature-controlled radiofrequency ablation device. In this single center retrospective study, a total of 62 consecutive patients with malignant biliary obstruction were evaluated. Thirty patients who underwent endobiliary radiofrequency ablation with metallic stent placement were in the study group and 32 patients who underwent only metallic stenting were in the control group. Outcomes of this study were technical success, complications related to the procedure, stent patency, and overall survival. All procedures were technically successful in both groups. There was no procedure-related mortality in either group. Procedural complication rates were similar between the groups. Although statistically not significant, the only two major complications (hemobilia requiring endovascular treatment) were in the control group. Median primary stent patency was significantly longer in the study group than in the control group (223 days vs. 158 days; P = 0.016). Median survival rates were also longer in the study group (246 days vs. 198 days; P = 0.004). Percutaneous endobiliary radiofrequency ablation is safe and feasible with this novel radiofrequency ablation device in patients with malignant biliary obstruction. Percutaneous endobiliary radiofrequency ablation has a potential to improve both stent patency and survival.
1 August 2021 in American Journal of Roentgenology
OBJECTIVE. The purpose of this study was to evaluate the safety and efficacy of transhepatic pharmacomechanical thrombectomy of symptomatic acute portomesenteric venous thrombosis. MATERIALS AND ME...
Background: Hepatic arterioportal fistulas are rare, abnormal, direct communications between hepatic artery and portal venous system. Treatment options shifted from surgery to endovascular interventions. Catheterization may be challenging. We report a case of a hepatic arterioportal fistula treated successfuly with Amplatzer Vascular Plug II via percutaneous transhepatic hepatic artery access after failed transfemoral approach. Case presentation: 58 year old woman presented with right heart failure, kidney insufficiency and massive ascites related to portal hypertension caused by hepatic arterioportal fistula. She had a history of previous abdominal surgery. Colour Doppler ultrasound and computed tomography revealed a giant portal vein aneurysm related to large hepatic areterioportal fistula. Endovascular treatment was planned. Catheterization of the hepatic artery could not be realized due to severe tortuosity and angulation of the celiac artery and its branches. Access to the hepatic artery was obtained directly via percutaneous transhepatic route and fistula site was embolized with Amplatzer Vascular Plug II and coils. Immediate thrombosis of the aneurysm sac and draining portal vein was observed. Patients clinical status improved dramatically. Conclusion: Transcatheter embolization is the first choice of the treatment of hepatic arterioportal fistulas but the type of the therapy should be tailored to the patient and interventional radiologist should decide the access site depending on his own experience if the routine endovascular access can not be obtained.
1 February 2021 in Journal of Vascular and Interventional Radiology
Objective: This study aimed to investigate the feasibility of low-dose chest CT acquisition protocol for the imaging of COVID 19 disease or suspects of this disease in adults. Method: In this retrospective case-control study, the study group consisted of 141 patients who were imaged with low dose chest CT acquisition protocol. The control group consisted of 92 patients who were imaged with standard protocol. Anteroposterior and lateral diameters of chest, effective diameter and scan length, qualitative and quantitative noise levels, volumetric CT dose index (CTDIvol), dose length product (DLP), and size-specific dose estimations were compared between groups. Results: Radiation dose reduction by nearly 90% (CTDIvol and DLP values 1.06 mGy and 40.3 mGy.cm vs. 8.07 mGy and 330 mGy.cm, respectively; p < 0.001) was achieved with the use of low-dose acquisition chest CT protocol. Despite higher image noise with low-dose acquisition protocol, no significant effect on diagnostic confidence was encountered. Cardiac and diaphragm movement-related artifacts were similar in both groups (p=0.275). Interobserver agreement was very good in terms of diagnostic confidence assessment. Conclusion: For the imaging of COVID-19 pneumonia or suspects of this disease in adults, lowdose chest CT acquisition protocol provides remarkable radiation dose reduction without adversely affecting image quality and diagnostic confidence.